The stock of Edwards Lifesciences Corporation (NYSE:EW) increased by increased by $0.85 on Friday to finish at $116.59, up 0.73 percent. The last five days have seen an average of 1,944,600 shares of common stock traded. 35 times new highs were reached in the current year, with a gain of $25.36. The average number of shares traded over the last 20 days was 2,376,075, while the average volume over the last 50 days totaled 2,068,708.
EW stock dropped -3.66% since last month. On 10/04/21, the company’s shares reached a one-month low of $105.66. The stock touched a high of $123.27 on 09/08/21, after rallying from a low of $70.92 in 52 weeks. The price of EW stock has risen by 27.80% or $25.36 this year, reaching a new high 35 times. Still, the stock price is down -5.42% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
There have been 7 days since Edwards Lifesciences Corporation (EW) last reported insider trading activity on Oct 18. On Oct 18, CVP, Critical Care Szyman Catherine M. sold 9,741 shares at $110.41 each. This transaction resulted in the insider making $1,075,482. On Oct 11, Wood Larry L sold 7,830 shares at a price of US$108.00. After the transaction, the insider now owns 372,134 shares. CVP,Strategy/Corp Development BOBO DONALD E JR had earlier sold 11,050 shares on Oct 08 for $110.49 a share. The transaction was completed for $1,220,881.
Edwards Lifesciences Corporation (EW) has a trailing price-to-earnings (P/E) ratio of 50.45. This level actually compares unfavorably with the industry at large, as the PE for the Medical Devices industry stands at about 43.29. Further, its PE also compares unfavorably with the Healthcare sector’s trailing 12 months PE ratio, which comes in at 33.43 right now. The PE ratio of Edwards Lifesciences Corporation has varied between 77.60 and 29.47 in the last five years. Beta for the stock is 1.00. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 14.65, the price-to-book (PB) ratio of 14.13, and the price-to-cash flow ratio of 68.65.
For the three months ended June 29, Edwards Lifesciences Corporation’s quick ratio was 2.90, while its current ratio was 3.70, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.12, and the total debt to equity ratio is 0.12. As far as profitability goes, gross margin for the trailing twelve months is 75.50% percent. Edwards Lifesciences Corporation’s EBITDA margin for the year ended June 29 was 32.63%, whereas its operating margin stood at 33.20% for the same period. Based on annual data, it had gross profit of $3.31 billion and revenue of $4.39 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. EW’s return on assets (ROA) during the last 12 months has been 20.20%. There was a 15.60% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 31.50%. ROE has averaged 3.96 in the past year for the broader industry.
According to Edwards Lifesciences Corporation’s quarterly financial report for the quarter that ended June 29, it had $595.4 million in total debt versus $248.4 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $1.38 billion, while revenues rose by 32.78% to $1.22 billion. It was predicted that Edwards Lifesciences Corporation’s quarterly earnings would be $0.64, but it ended up being $0.56, beating the consensus by 14.30%. EBITDA was $577.9 million for the quarter. At the end of Edwards Lifesciences Corporation’s most recent quarter ended June 29, its liabilities totaled 2.53 billion, while its total debt was $684.2 million. Equity owned by shareholders amounts to $623.33 million.
Here’s a quick look at Edwards Lifesciences Corporation’s (EW) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 65.76%, suggesting the stock is Neutral, with a 18.22% historical volatility rate.
The stochastic %K and %D were 95.04% and 89.92% respectively, while the average true range (ATR) was 2.42. Based on the 14-day stochastic reading of 96.25%, the RSI (14) reading is 58.36%. On the 9-day MACD Oscillator, the stock is at 3.13, and the 14-day reading is at 4.40.
In a note to investors, Wells Fargo maintained its an Equal weight rating on Edwards Lifesciences Corporation (NYSE: EW). However, the firm raised their price target to $115, indicating a possible decrease of -25.37% in the stock price. Analysts have assigned Edwards Lifesciences Corporation (EW) an Overweight rating. EW is a stock that is recommended for selling by 0 brokerage firms, while 11 companies recommend holding. The stock is underweighted by 1 analyst. Among the analysts who rate the stock, 2 rates it overweight and 13 others recommend it as a buy.
What is EW’s price target for the next 12 months?
The current consensus forecast for the stock is between $105.00 and $135.00, with a median target price of $123.00. In analyzing these forecasts, the average price target given by analysts for Edwards Lifesciences Corporation (EW) is $121.48.